Federico Hinestrosa, MD, FACP, FIDSA
Associate Medical Director
- American College of Physicians, FACP since 09/2014
- Infectious Diseases Society of America
- HIV Medicine Association
- International Society for Infectious Diseases
- American Academy of HIV Medicine
- HIV Specialist through American Academy of HIV Medicine
Publications
- Sulkowski MS, Gardiner DF, Rodriguez-Torres M, Reddy KR, Hassanein T, Jacobson I, Lawitz E, Lok AS,Hinestrosa F, Thuluvath PJ, Schwartz H, Nelson DR, Everson GT, Eley T, Wind-Rotolo M, Huang S-P, Gao M, Hernandez D, McPhee F, Sherman D, Hindes R, Symonds W, Pasquinelli C, and Grasela DM. Daclatasvir plus Sofosbuvir for Previously Treated or Untreated Chronic HCV. N Engl J Med. 2014 Jan 16;370(3):211-21.
- Wyles D, Ruane PJ, Sulkowski MS, Dieterich D, Luetkemeyer A, Morgan TR, Sherman KE, Dretler R, Fishbein D, Gathe JC, Henn S, Hinestrosa F, Huynh C, McDonald C, Mills A, Turner E, Ramgopal M, Rashbaum B, Ray G, Scarsella A, Yozviak J, McPhee F, Liu Z, Hughes E, Yin PD, Noviello S, Ackerman P, ALLY-2 Investigators. Daclatasvir plus Sofosbuvir for Chronic HCV in Patients Coinfected with HIV. N Engl J Med. 2015 Jul 21.
- Everson GT, Sims KD, Thuluvath PJ, Lawitz E, Hassanein T, Rodriguez-Torres M, Desta T, Hawkins T, Levin JM, Hinestrosa F, Rustgi V, Schwartz H, Younossi Z, Webster L, Gitlin N, Eley T, Huang SP, McPhee F, Grasela DM, Gardiner DF. Daclatasvir + Asunaprevir + Beclabuvir ± Ribavirin for Chronic HCV Genotype 1-Infected Treatment-Naive Patients. Liver Int. 2016 Feb;36(2):189-97.
- Everson GT, Towner W, Davis M, Wyles D, Nahass R, Thuluvath PJ, Etzkorn K, Hinestrosa F, Tong MJ, Rabinovitz M, McNally J, Brainard D, Han L, Doehle B, McHutchison JG, Morgan T, Chung R, Tram T. Sofosbuvir with GS-5816 in treatment-naïve genotype 1-6 hepatitis C patients: a randomized, Phase 2 trial. Ann Intern Med. 2015 Dec 1;163(11):818-26.
- Lawitz E, Reau N, Hinestrosa F, Rabinovitz M, Schiff E, Sheikh A, Younes Z, Herring R Jr, Reddy KR, Tran T, Bennett M, Nahass R, Yang JC, Lu S, Dvory-Sobol H, Stamm LM, Brainard DM, McHutchison JG, Pearlman B, Shiffman M, Hawkins T, Curry M, Jacobson I. Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients with Genotype 1 Hepatitis C Virus Infection in an Open-label, Phase 2 Trial. Gastroenterology. 2016 Jul 30. pii: S0016-5085(16)34835-1.
Presentations
- Combination of Daclatasvir, Asunaprevir, and BMS-791325 for 12 Weeks in Treatment-Naive Patients With Chronic HCV Genotype 1 Infection (Oral Presentation). Accepted at AASLD The Liver Meeting, Washington, DC, USA. November 1-5, 2013.
- All-Oral Combination of Daclatasvir, Asunaprevir, and BMS-791325 for HCV Genotype 1 Infection (Oral Presentation). Accepted at CROI, Boston, MA, USA. March 3-6, 2014.
- Safety and Efficacy of Treatment with Sofosbuvir+GS-5816+/-Ribavirin for 8 or 12 Weeks in Treatment Naïve Patients with Genotype 1-6 HCV Infection (Oral Presentation). Accepted at AASLD The Liver Meeting, Boston, MA, USA. November 7-11, 2014.
- Daclatasvir in combination with asunaprevir and BMS-791325 for prior null responders with chronic HCV genotype 1 infection (Oral Presentation). Accepted at AASLD The Liver Meeting, Boston, MA, USA. November 7-11, 2014.
- Sofosbuvir/Velpatasvir in Combination With Ribavirin for 24 Weeks Is Effective Retreatment for Patients Who Failed Prior NS5A-Containing DAA Regimens: Results of the Retreatment Study (Oral Presentation). Accepted at EASL The International Liver Congress, Barcelona, Spain. April 13 – 17, 2016.
- High Efficacy of Sofosbuvir/Velpatasvir Plus GS-9857 for 12 Weeks in Treatment-Experienced Genotype 1-6 HCV-Infected Patients, Including Those Previously Treated With Direct-Acting Antivirals (Oral Presentation). Accepted at EASL The International Liver Congress, Barcelona, Spain. April 13 – 17, 2016.
Dr. Hinestrosa received his medical degree in 1997, from the Universidad CES in Medellin, Colombia. He completed his Internal Medicine training at Geisinger Medical Center in Danville Pennsylvania and his Infectious Disease Fellowship at Washington Hospital Center/Georgetown University in Washington DC. He is a certified HIV Specialist through the American Academy of HIV Medicine (AAHIVM)
Dr. Hinestrosa is Board-certified in internal medicine and infectious diseases by the American Board of Internal Medicine. Dr. Hinestrosa became a Fellow of the American College of Physicians. Before joining the Orlando Immunology Center in 2009, Dr. Hinestrosa was an HIV/AIDS Primary Care Consultant at Andromeda Transcultural Health in Washington, DC.
“Dr. Hinestrosa is the best. If you have any problems with your liver he is the doctor. He has saved my life.”
– Healthgrades Review
Dr. Hinestrosa was named the Associate Medical Director of OIC in 2017. Besides his clinical duties at OIC, he also plays investigatory roles on the Orlando Immunology Center’s HCV and HIV clinical trials. Dr. Hinestrosa is a member of the Infectious Diseases Society of America, HIV Medicine Association, and American Academy of HIV Medicine. He has contributed original articles to the medical literature, and has presented abstracts at professional society annual meetings, including the American Association for the Study of Liver Diseases and European Association for the Study of the Liver.
